Dry Powder Inhaler Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The dry powder inhaler market size has grown strongly in recent years. It will grow from $21.25 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to renewed interest in sustainable building materials, cultural preservation and heritage restoration, rise in green building practices, local sourcing and community involvement, regulatory support and building codes.

The dry powder inhaler market size is expected to see steady growth in the next few years. It will grow to $27.13 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to continued emphasis on sustainability, global urbanization trends, advancements in manufacturing processes, government incentives and policies, global economic factors. Major trends in the forecast period include increased research and development, renewed interest in traditional building techniques, advancements in material technology, architectural and design trends, regulatory support for sustainable construction.

The increasing prevalence of respiratory diseases is anticipated to boost the growth of the dry powder inhaler market in the future. Respiratory diseases encompass a wide range of disorders affecting the respiratory system, including various lung diseases. Dry powder inhalers play a critical role in treating respiratory conditions such as asthma, COPD, and cystic fibrosis by delivering medication directly to the lungs, where it is most effective. This method serves as a promising alternative to traditional drug delivery techniques for respiratory issues. For example, a study published in December 2023 by JAMA Network Open, a medical journal of the American Medical Association, indicates that the global burden of chronic obstructive pulmonary disease (COPD) is projected to nearly reach 600 million cases worldwide by 2050, reflecting a 23% increase in prevalence. Notably, cases among females are expected to surge by 47.1%, while male cases are projected to rise by only 9.4%. Additionally, the majority of these cases are expected to occur in low- and middle-income regions, where the prevalence is anticipated to be more than double that of high-income areas by 2050. Consequently, the growing prevalence of respiratory diseases will significantly drive the expansion of the dry powder inhaler market.

The increasing levels of air pollution are also anticipated to contribute to the growth of the dry powder inhaler market. Air pollution, measured by the concentration of various pollutants in the atmosphere, leads to respiratory issues, making dry powder inhalers a preferred delivery method for medications that alleviate symptoms and manage respiratory conditions exacerbated by airborne pollutants. In 2022, the United States Environmental Protection Agency reported approximately 66 million tons of pollutants released into the atmosphere in the United States. Additionally, in March 2023, IQAir reported that Iraq was the second most polluted country with 80.1 µg/m3, 16 times higher than the WHO PM2.5 annual guideline in 2022. Therefore, the rising levels of air pollution are expected to drive the growth of the dry powder inhaler market.

Key players in the dry powder inhaler market are focusing on developing innovative products featuring muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD) while also expanding their product portfolios. Muscarinic antagonists are drugs that inhibit the muscarinic acetylcholine receptor, and they are used to manage various conditions, including COPD and organophosphate poisoning. For example, in March 2024, Berry Global, a US-based company recognized for its development and manufacturing of diverse flexible packaging solutions, unveiled its new dry powder inhaler at Pharma Pack. This inhaler is specifically designed to improve drug delivery for respiratory conditions such as COPD and asthma, providing a customizable solution for pharmaceutical companies.

In August 2024, Aptar Pharma, a US-based specialist in drug delivery, acquired the Orbital Dry Powder Inhaler for an undisclosed sum. This acquisition strengthens Aptar's capabilities in respiratory drug delivery, especially for managing conditions such as asthma and chronic obstructive pulmonary disease (COPD). The Orbital Dry Powder Inhaler is noted for its innovative design, which enhances medication delivery. This acquisition aligns with Aptar Pharma's strategy to expand its product offerings and reinforce its position in the respiratory treatment market. The Orbital DPI operates within the pharmaceutical and medical device sectors in India.

Major companies operating in the dry powder inhaler market report are Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Boehringer Ingelheim GmbH, Viatris (Mylan N.V), Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Catalent Inc., Aptar Group Inc., Chiesi Farmaceutici S.p.A., Recipharm AB, Cipla Limited, Lupin Limited, Orion Corporation, OPKO Health, Zhejiang Hisun Pharmaceutical Co Ltd., Beximco Pharmaceuticals Ltd., Sava Healthcare Ltd., Hovione, Elpen S.A., MannKind Corporation, Meda Pharmaceuticals, Presspart Manufacturing Ltd., SMB Laboratories SA, Teva Pharmaceutical Industries Limited, Pharmaxis Ltd., Iconovo AB, SRS Pharmaceuticals Pvt. Ltd.

North America was the largest region in the dry powder inhaler market in 2024. The regions covered in the dry powder inhaler market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Dry Powder Inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dry powder inhaler market consists of sales of dry powder forms, spiriva handihalers, breath-activated inhalers, rotahalers, diskus devices, and twisthaler inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A dry powder inhaler (DPI) is a medical device designed for delivering medication in the form of dry powder directly to the lungs. It is primarily used for treating respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). To effectively use a DPI, it is crucial for the user to inhale rapidly and deeply, allowing the medication to reach the lungs.

The main types of dry powder inhalers include single-dose inhalers and multi-dose inhalers. Single-dose inhalers are devices that administer medication directly to the lungs in the form of dry powder. These devices can be either manually operated or digitally operated, and they find applications in treating conditions such as asthma, COPD, cystic fibrosis, and others. Various end-users, including hospitals and clinics, homecare settings, and ambulatory surgical centers, utilize these inhalers.

The dry powder inhaler market research report is one of a series of new reports that provides dry powder inhaler market statistics, including dry powder inhaler industry global market size, regional shares, competitors with a dry powder inhaler market share, detailed dry powder inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the dry powder inhaler industry. This dry powder inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.